Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05993949 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Jun 2027 to Jul 17, 2025
    • Study completion pushed from Jun 2027 to Jun 2040
    • Eligibility criteria expanded, about 37 words
  2. Primary and study completion dates: Aug 2025 to Jun 2027
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 8
    • Site details revised
    v6
  3. Collaborator revisedv5
  4. Re-verified, no change to tracked fieldsv4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 15, 2023 to Oct 2, 2023
    • Site details revised
    v3
  6. Start date: Aug 2023 to Oct 15, 2023v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
Trial Details
NCT Number NCT05993949
Lead Sponsor Stanford University
Collaborators: Kite, A Gilead Company
Conditions
(from sponsor)		 Lymphoblastic Leukemia
Related terms Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov